NCT02890758 2023-02-21Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803Case Comprehensive Cancer CenterPhase 1 Completed14 enrolled
NCT01885897 2020-08-12IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTMasonic Cancer Center, University of MinnesotaPhase 1/2 Completed33 enrolled 15 charts